TandemAI, a Suzhou, and Shanghai, China- and New York-based technology company focused on transforming drug discovery infrastructure, raised $35M in Series A funding.
The round was led by Qiming Venture Partners with participation from OrbiMed, Eight Roads Ventures, and F Prime Capital. In connection with the financing, Kan Chen, Partner at Qiming Venture Partners, will join the TandemAI board of directors.
The company intends to use the funds to to increase its wet lab capacity to over 500 chemists and biologists and continue the development of its computational tools to service the expanding biotech client base in the U.S. and China.
Led by CEO Jeff He, MBA, TandemAI provides a drug discovery service platform that integrates computational tools with wet lab biophysics, medicinal chemistry, and biology to empower researchers to discover better therapeutic candidates faster and more efficiently.
The company’s client base currently includes about 50 companies.
FinSMEs
01/03/2023